Aug 2, 2023 | Press Release
OVERLAND PARK, Kan. – August 2, 2023 – Dr. Vince Clinical Research (DVCR), a full-service CRO specializing in Phase I-II clinical trials, announced today the first subject was screened for Cessation Therapeutics’ CSX-1004 in a First-In-Human single ascending...
Jun 27, 2023 | Press Release
OVERLAND PARK, Kan. – June 27, 2023 – Dr. Vince Clinical Research, a full-service Phase I-II contract research organization (CRO), announced its world-class clinical pharmacology unit, which opened in September, was awarded two Green Globes certifications....
Jan 11, 2023 | Press Release
OVERLAND PARK, KS – January 10 2023 – Dr. Vince Clinical Research (DVCR), an early phase CRO specializing in Phase 1 trials, announced that it has administered the first dose of Aclaris Therapeutics’ ATI-2138, in a Phase 1 multiple ascending dose (MAD)...
Recent Comments